Who are Anti-Arrhythmic therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cordarone, Intravenous amiodarone(1), Ezogabine/Retigabine IR, minoxidil + finasteride, (C) D-V14, Levosimendan infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-arrhythmic-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Anti-Arrhythmic therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-Arrhythmic therapy (Anti-Arrhythmic therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Class I anti-arrhythmic. Area: Cardiovascular.

phase 1 Class I anti-arrhythmic Potassium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Anti-Arrhythmic therapy (Anti-Arrhythmic therapy) — Imperial College London. Blocks potassium channels to prevent arrhythmias

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-Arrhythmic therapy TARGET	Anti-Arrhythmic therapy	Imperial College London	phase 1	Class I anti-arrhythmic	Potassium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
Intravenous amiodarone(1)	Intravenous amiodarone(1)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors
Ezogabine/Retigabine IR	Ezogabine/Retigabine IR	GlaxoSmithKline	marketed	Potassium channel opener	Kv7 (KCNQ) voltage-gated potassium channels
minoxidil + finasteride	minoxidil + finasteride	Beijing Dayspring Pharmaceutical Technology Co., Ltd	marketed	Combination antialopecia agent	Potassium channels (minoxidil); 5-alpha reductase type II (finasteride)
(C) D-V14	(C) D-V14	National Taiwan University Hospital	marketed	Antiarrhythmic	Potassium channels
Levosimendan infusion	Levosimendan infusion	AHEPA University Hospital	marketed	Calcium sensitizer / inodilator	Cardiac troponin C; ATP-sensitive potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Class I anti-arrhythmic class)

Imperial College London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-Arrhythmic therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-arrhythmic-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab